Pathology Industry in Germany: Market Research Reports, Statistics and Analysis

Company Report: Pathology In Germany For Year 2012

... Become potentially very attractive. Sirtex S largest trial assesses liver cancer suffes Response to a combination of chemotherapy and its radioactive beads, and results will be published as soon ...

Mologen Ag - Company Report For Year 2012

... Improving the economic prospects for mologen. The initial analysis of the phase ii colorectal cancer study showed a significant prolongation of progression-free survival for the study patients treated ...

Company Report: Pathology In The United States And Germany For Ye ...

... That have the potential to substantially lengthen and improve the lives of critically ill patients in areas of major unmet medical need. The company's most advanced investigational agent is talactoferrin alfa ...

Cardiovascular Disease Sector In Germany And France

... Unit dose for cerebrovascular diseases being different from that for all cardiovascular diseases there is some evidence that risk at a few hundred milligray is lower than that obtained by the lnt ...

Pharmaceutical Key Market Figures In Germany, South Korea And Th ...

... In an attempt to derive more internationally comparable results. Disease specific costing studies Mental health Combine with more detailed data cancer Rmch next steps (2) Final guidelines ...

Global Pharmaceutical Sector Brief Analysis

... Including global investigator-initiated trials (iits) in multiple indications: hcc, net, crc, melanoma establish chemosat as the standard of care (soc) for disease control in the liver 16 delcath systems ...

Cancer Market In The United States And Germany

Pharmaceutical Sector Analysis In The United States And Germany

... Drug/device combination product regulated as a drug 505(b)(2) nda by u.S. Fda Proposed indication for the treatment of patients with unresectable ocular melanoma metastatic to the liver Melblez ...

Heart Disease Industry Statistics In Spain And Germany